OncoMatch/Clinical Trials/NCT01492972
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Is NCT01492972 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Androgen Suppression Therapy for prostate cancer.
Treatment: Androgen Suppression Therapy — The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy (28 treatments) alone to proton therapy with androgen suppression therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage T2C (AJCC 7th Ed.)
Clinical stages T1-T2c N0 M0 as staged by the treating investigator. (AJCC Criteria 7th Ed.- appendix III).
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: prostatectomy
Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery.
Cannot have received: hyperthermia
Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery.
Cannot have received: cryosurgery
Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery.
Cannot have received: pelvic radiation
Previous pelvic radiation for prostate cancer.
Cannot have received: androgen suppression therapy
Previous androgen suppression therapy for prostate cancer.
Cannot have received: systemic chemotherapy
Prior systemic chemotherapy for prostate cancer.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Scottsdale, Arizona
- Northwestern Medicine Chicago Proton Center · Warrenville, Illinois
- Oklahoma Proton Center · Oklahoma City, Oklahoma
- Hampton University Proton Therapy Institute · Hampton, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT01492972 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior prostatectomy, hyperthermia, cryosurgery disqualifies patients from enrollment.
What disease stage is eligible?
Stage T2C is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages